Plant protection product dossier
See how ready your plant protection product dossier is, section by section, and what each gap needs.

ProjectsPlant protection product dossier
- Marta Kowalczyk
- Henrik Solberg
- Zainab Rahman
| Section | Complete | Owner | Status |
|---|---|---|---|
| Identity and composition | 100% | Formulation team | Complete |
| Efficacy | 45% | Field trials team | At risk |
| Analytical methods | 90% | Analytical lab | In review |
| Toxicology | 82% | Tox consultant | In review |
| Residues | 76% | Residues team | In progress |
| Environmental fate | 64% | Fate consultant | In progress |
| Ecotoxicology | 58% | Ecotox consultant | In progress |
| Comparative assessment | 0% | Regulatory affairs | Not started |
Efficacy Potatoes
Status: At riskMay need a second season in 2027
- Requires
- Trials in at least two growing seasons
- Trials
- One season, 2026
- Unless
- The 2026 trials confirm an extrapolation
Your expert signs off each regulation
You get the readiness view, a map of every data point your product needs, agreed before any checking starts, and a record of each decision with its evidence.

Approval
Illustrative projectMarta Kowalczyk
Status: ApprovedHead of Regulatory Affairs, after checking each section against the 3 regulations behind the dossier
Regulation (EC) No 1107/2009, authorisation
Regulation (EU) No 284/2013, data requirements
Regulation (EU) 2026/1120, co-formulants
Foresight does the research
Your team brings what only it knows, and your expert makes the call at each checkpoint.

Tasks
Status: In progressIllustrative project3 of 5 tasks done.
Share your product and studies
Your team
Status: DoneMap the requirements
Foresight
Status: DoneAgree the requirements
CheckpointStatus: ApprovedMarta Kowalczyk
Check the evidence
Foresight
Status: In progressApprove the review
CheckpointStatus: Not startedMarta Kowalczyk
Kept current once it’s approved
Monitoring watches the measures behind your dossier. When one moves, Foresight rechecks the sections it affects, and your expert reviews the change.

Monitoring
Illustrative projectWatching 4 measures behind the dossier
Azoxystrobin approval
Difenoconazole approval
- Status: To review
Unacceptable co-formulants, Annex III to Regulation (EC) No 1107/2009
Regulation (EU) 2026/1120 added 12 co-formulants, in force from 16 June 2026. Rechecked, none is in the product above 0.1%.
Draft amendment to Regulation (EU) No 284/2013
What we need from you
Four things, shared at setup before the project starts.
Your product
The product’s composition and specification, with its active substances and co-formulants.
Your uses
The crops, diseases and rates you’ll apply for, and the Member States in the zone.
Your studies
The study reports you hold or can access, who owns each section, and when you plan to submit. A study list with an owner for each section is enough to start.
Your approver
The person who agrees the requirements map and approves the review.
What teams ask about this project
How do you structure the dossier?
In the draft Registration Report (dRR) format used for zonal applications: Part A for each Member State’s risk management, Part B for the core assessment, section by section, and Part C for confidential information. Each section is broken into the data points Regulation (EU) No 284/2013 sets for products, and each data point is matched to the study or reasoned case that answers it.
Where does the evidence come from?
From your study reports, the EU-agreed endpoints for each active substance, and the regulations and guidance behind each requirement. Every status links to its source, so your team can check it directly.
What changes when an active substance is a candidate for substitution?
Each Member State concerned runs its own comparative assessment under Article 50 of Regulation (EC) No 1107/2009. It must refuse or restrict a use where a significantly safer alternative exists without significant economic or practical drawbacks, and enough chemical diversity remains to manage resistance. Difenoconazole is a candidate for substitution, so the dossier tracks the case for each use in Part A.
Who checks the review before we use it?
The person you name. They agree the requirements map before checking starts, and check each section’s status against its evidence at the end. Nothing is final until they approve it. These checks reduce the risk of error without removing it.
What happens when a rule changes?
Foresight rechecks the sections it affects, such as when an active substance’s approval or the list of unacceptable co-formulants changes. The review your expert approved stays as it is until they accept the change.
What does it cost?
The price follows the dossier’s size: how many uses, Member States and studies it covers. You see it with the scope, before any checking starts.
More ways to meet an obligation
Each runs the same way, with your expert approving the result.
- PPWR compliance programmePackaging requirements, milestones, and evidence in one plan.
- EPR reportingPackaging and product data prepared for each country’s EPR scheme and deadline.
- REACH registration dossiersEU and UK REACH registrations, from data gap analysis to a dossier ready to submit.
- CLP classification and labellingMixture classifications under CLP, and the label elements that follow.
- Poison centre notificationsCLP Annex VIII notifications, with a UFI for each mixture.
- SCIP notificationsArticles with Candidate List substances above 0.1%, prepared for ECHA’s SCIP database.
- TSCA reportingInventory status, CDR and PFAS reports for substances you make in or import into the US.
- Biocidal product dossierProduct authorisation dossiers under the EU Biocidal Products Regulation.
Bring your study list to a demo
Tell us your product, its uses and the zone you’re applying in. You’ll see the scope and the price before any checking starts.
